We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

14 hedge funds and large institutions have $8.5M invested in Soleno Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

8% more funds holding

Funds holding: 13 → 14 (+1)

4% more capital invested

Capital invested by funds: $8.18M → $8.5M (+$315K)

0.01% less ownership

Funds ownership: 0.46% → 0.45% (-0.01%)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$78.9K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$75.9K
3
VF
Virtu Financial
New York
+$27.8K
4
TSS
Two Sigma Securities
New York
+$23.3K
5
Citadel Advisors
Citadel Advisors
Florida
+$14.4K

Top Sellers

Rank Fund Capital Flow
1
PAI
Palo Alto Investors
California
-$178K
2
SM
Sabby Management
Florida
-$127K
3
BG
Bollard Group
Massachusetts
-$96K
4
Goldman Sachs
Goldman Sachs
New York
-$9.86K
5
Bank of America
Bank of America
North Carolina
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$7.64M – – –
Deutsche Bank
2
Deutsche Bank
Germany
$311K +$13.5K +342 +4%
PAI
3
Palo Alto Investors
California
$220K -$178K -4,520 -80%
Vanguard Group
4
Vanguard Group
Pennsylvania
$105K +$75.9K +1,925 +249%
6CM
5
683 Capital Management
New York
$78K +$78.9K +2,000 New
BlackRock
6
BlackRock
New York
$41K +$197 +5 +0.5%
VF
7
Virtu Financial
New York
$28K +$27.8K +706 New
TSS
8
Two Sigma Securities
New York
$23K +$23.3K +590 New
Renaissance Technologies
9
Renaissance Technologies
New York
$14K +$14K +354 New
Citadel Advisors
10
Citadel Advisors
Florida
$14K +$14.4K +365 New
UBS Group
11
UBS Group
Switzerland
$9K +$6.51K +165 +284%
Northern Trust
12
Northern Trust
Illinois
$7K – – –
Goldman Sachs
13
Goldman Sachs
New York
$5K -$9.86K -250 -65%
Morgan Stanley
14
Morgan Stanley
New York
$1K -$197 -5 -26%
SM
15
Sabby Management
Florida
– -$127K -3,308 Closed
BG
16
Bollard Group
Massachusetts
– -$96K -2,563 Closed
Bank of America
17
Bank of America
North Carolina
– -$3K -91 Closed
Creative Planning
18
Creative Planning
Kansas
– -$1K -17 Closed

SLNO Hedge Fund Activity: Q3 2017 in Review

14 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2017, worth a combined $8.5M — up 3.8% from $8.18M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SLNO positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $78.9K. The largest seller was Palo Alto Investors, cutting an estimated $178K.

  • 14 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2017, up from 13 in Q2 2017.
  • Funds reported $8.5M of Soleno Therapeutics stock for Q3 2017, up 3.8% quarter-over-quarter.
  • 5 funds opened new Soleno Therapeutics positions in Q3 2017 and 4 closed out, a net change of +1 holder.
  • The largest Soleno Therapeutics buyer in Q3 2017 was 683 Capital Management, an estimated $78.9K added.
  • The largest Soleno Therapeutics seller in Q3 2017 was Palo Alto Investors, an estimated $178K sold.

Based on aggregated 13F filings for Q3 2017.